.jpg "Dynavax Received its Third Buy in a Row")
After Cantor Fitzgerald and William Blair assigned a Buy rating to Dynavax in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Phil Nadeau maintained a Buy rating on Dynavax (NASDAQ: DVAX) yesterday and set a price target of $30. The company’s shares opened today at $16.05.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.0% and a 50.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.
Currently, the analyst consensus on Dynavax is Strong Buy and the average price target is $29.40, representing an 83.2% upside.
In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.45 and a one-year low of $5.35. Currently, Dynavax has an average volume of 1.5M.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor biology to discover and develop novel vaccines and therapeutics. The company’s development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.
Read More on DVAX:
